Biogen’s (other) big risk went away
The multibillion-dollar uncertainty haunting Biogen disappeared yesterday.
As STAT’s Adam Feuerstein reports, a federal panel ruled against Mylan in its effort to dispute a key patent to Biogen’s best-selling drug, a multiple sclerosis therapy called Tecfidera. Thanks to the ruling a drug that brings in about $4 billion a year for Biogen won’t face generic competition until 2028. Had Mylan prevailed, a generic Tecfidera could have entered the market as early as next year.
We still don’t know the fate of aducanumab, the company’s controversial treatment for Alzheimer’s disease, but the end of the Tecfidera drama added about $11 billion to Biogen's valuation.
Read more.
As STAT’s Adam Feuerstein reports, a federal panel ruled against Mylan in its effort to dispute a key patent to Biogen’s best-selling drug, a multiple sclerosis therapy called Tecfidera. Thanks to the ruling a drug that brings in about $4 billion a year for Biogen won’t face generic competition until 2028. Had Mylan prevailed, a generic Tecfidera could have entered the market as early as next year.
We still don’t know the fate of aducanumab, the company’s controversial treatment for Alzheimer’s disease, but the end of the Tecfidera drama added about $11 billion to Biogen's valuation.
Read more.
.png)
No hay comentarios:
Publicar un comentario